Medtronic’s Symplicity Spyral Shows Sustained Blood Pressure Reduction at Three Years

Medtronic has released three-year results from its SPYRAL HTN-ON MED trial, showing that patients treated with its Symplicity Spyral renal denervation (RDN) system maintained significant blood pressure reductions compared with a sham group.

At three years, 24-hour ambulatory systolic blood pressure dropped by 14.0 mmHg in the RDN group versus 9.3 mmHg in the sham group, while office-based readings fell 18.5 mmHg versus 11.7 mmHg, respectively. Although the treatment gap narrowed slightly over time, RDN patients continued to show clinically meaningful improvements despite comparable medication use.

No cases of renal artery stenosis above 70% were observed, underscoring the long-term safety of Symplicity Spyral. The FDA-approved device, which uses radiofrequency energy to ablate renal nerves, remains central to Medtronic’s strategy amid pending Medicare coverage decisions—a move that could accelerate adoption in the growing RDN therapy market.

02-11-2025